JAMA: Plasma P-tau217 levels are important biomarkers for the identification of Alzheimer's disease.

Recently, researchers examined the effects of plasma suchenosine 217 (P-tau217) tau phosphorylation as a diagnostic biomarker for AD.
researchers looked at three cross-sectional queue data: Arizona-based neuropathological cohort (cohort 1), comprising 34 AD patients and 47 non-AD patients; participants in n-178, AD dementia (n-121) and other neurodegenerative diseases (n-99), as well as the Colombian autosomal dominant AD family (queue 3), including 365 PSEN1 E280A mutation carriers and 257 non-carriers of mutations.
plasma P-tau217 content analysis was performed on all participants. The main result of
study was the accuracy of plasma P-tau217's identification of AD (clinical or neuropathological diagnosis).
secondary results are associated with tau pathology (determined by neuropathology or positron emission tomography (PET). The average age of the participants in the
queue 1 was 83.5 years, 38% female, the average age of the participants in queue 2 was 69.1 years, the female was 51%, and the average age of the participants in queue 3 was 35.8 years and the female was 57%.
in queue 1, the patient's pre-life plasma P-tau217 neuropathologically distinguishes AD and non-AD (the area under the curve is 0.89) the accuracy is significantly higher than that of plasma P-tau181 and nerve wire light chain (NfL) (AUC range: 0.50-0.72).
in queue 2, plasma P-tau217 significantly outperformed the identification accuracy of clinical AD dementia and other neurodegenerative diseases (AUC: 0.96) than plasma P-tau181, plasma NfL and MRI measurements (AUC range: 0.50-0.81), but compared to cerebrospinal fluid P-tau217, CSF-P181 and PET-pet.
in queue 3, the level of plasma P-tau217 in pSEN1 mutant carriers increased significantly, and for patients over 25 years of age, the estimated mcI onset time of the mutant carriers was 20 years ahead.
plasma p-ta217 levels are associated with tau protein thesphenosis.
plasma p-ta217 levels in queue 1 were associated with amyloid plaques.
in queue 2, the accuracy of plasma P-tau217 identification (AUC: 0.93) was significantly higher than that of plasma P-tau181, plasma NfL, CSF P-tau181, CSF A beta 42/A beta 40 and MRI measurements (AUC range, 0.67-0.90), but its performance was significantly different from CSF P-tau217.96.
studies suggest that plasma P-tau217 is an effective clinical method to distinguish between Alzheimer's disease and neurodegenerative diseases.
.